Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)

NCT05771584 is registered in ClinicalTrials.gov with Aston Sci. Inc. as lead sponsor.

NCT NCT05771584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05771584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)
Lead sponsor
Aston Sci. Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 4, 2023
Completion date
May 31, 2027
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer